Explains Supplementary protection certificate for mini-pill "Cerazette" void

Explains Supplementary protection certificate for mini-pill "Cerazette" void

The Federal Patent Court ruled in its judgment of 6. More 2014 (3 NI 21/12) The SPC DE 199 75 011 for the active ingredient desogestrel - the active ingredient in the mini-pill sold under the brand “Cerazette” - was declared null and void following an action by ratiopharm GmbH.

Key message

A supplementary protection certificate is required in accordance with Art. 15 Abs. 1 BUCHST. c of the regulation (EG) No.. 469/2009 void, if the underlying patent was not legally valid due to a lack of inventive step. This can also be checked after the basic patent has expired.

Facts

The basic patent EP 0 491 443 concerned a contraceptive pack with daily dosage units of 70 to 80 Micrograms of desogestrel as the only active ingredient. It ran in December 2011 AB, the protection certificate in December 2012. The applicant, against the violation- and claims for damages were in question, attacked the certificate because of a lack of inventive step and, alternatively, because of an earlier approval of desogestrel in combination preparations.

The decision

The Senate considered all patent claims to be obvious. Scientific publications from the years 1976 to 1982 have already described desogestrel as a highly effective progestogen with complete ovulation inhibition and have suggested studies with desogestrel alone. carried out. The dose of 70 to 80 Micrograms lie between known effective doses and can be determined through routine dose determination. Claimed advantages are merely the result of an obvious action.

The owner's objection, The state of the art only targets combination preparations, the court rejected. The long period between publication and registration does not constitute an inventive step. Whether the certificate also violates Art. 3 violated the regulation, the Senate left it open.

Importance for practice

A protection certificate is only as strong as the basic patent. Generic drug manufacturers can challenge certificates of the patentability of the basic patent, even after it expires, if they are threatened with claims. An appeal to the Federal Court of Justice against the judgment was permitted; the summary reflects the status at the time of the judgment.

Full text: rechtsprechung-im-internet.de (CERTIFICATE 3 NI 21/12)

You have a similar question? More about our advice on objections and nullity or make an appointment.

Summary of the decision; no legal advice in individual cases.

Horak Attorneys

Leave a Reply

Proudly powered by WordPress | Blog: Stacy by SpiceThemes